$3.85
0.0751.99%
Last update: Nov 6, 11:29 AM
Relmada Therapeutics Inc
RLMDNASDAQ
The average analyst price target for Relmada Therapeutics is $10, 160.1% above the current price. Of 7 analysts, 6 rate it Buy and 1 Sell. Targets range from $1 to $19. The latest change came on Jun 18, 2026, when HC Wainwright & Co. initiated coverage of Relmada Therapeutics with a Buy rating and a $12 price target.
Price Target Range — 6 Quarters
Analyst Consensus — 7 Analysts
Rating Trend — Last 9 Months
